Does Rallies show 13F holders for MRNA?

Yes. Rallies tracks hedge fund and 13F ownership data for MRNA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MRNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.

MRNA (Moderna) Stock Analysis - Hedge Fund Holdings

Moderna (MRNA) is a publicly traded Healthcare sector company. As of May 20, 2026, MRNA trades at $48.28 with a market cap of $19.09B and a P/E ratio of -5.92. MRNA moved +5.33% today. Year to date, MRNA is +48.15%; over the trailing twelve months it is +73.25%. Its 52-week range spans $22.28 to $67.96. Analyst consensus is neutral with an average price target of $44.73. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MRNA stock?

Hedge funds tracked by Rallies that own MRNA include Matrix Capital, Coatue Management, Bridgewater Associates, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Moderna.

MRNA Key Metrics

Key financial metrics for MRNA
Metric	Value
Price	$48.28
Market Cap	$19.09B
P/E Ratio	-5.92
EPS	$-8.15
Dividend Yield	0.00%
52-Week High	$67.96
52-Week Low	$22.28
Volume	3.87M
Avg Volume	0
Revenue (TTM)	$2.23B
Net Income	$-3.19B
Gross Margin	22.11%

Top Hedge Funds Holding MRNA

Matrix Capital holds 730.00K shares of MRNA, changed +60.79% as of Mar 31, 2024.
Coatue Management holds 400.00K shares of MRNA, changed +109.34% as of Dec 31, 2025.
Bridgewater Associates holds 74.82K shares of MRNA, changed +392.87% as of Mar 31, 2026.
Panagora Asset holds 42.52K shares of MRNA, changed -4.99% as of Mar 31, 2026.
Mangrove Partners holds 21.03K shares of MRNA, changed +0.00% as of Mar 31, 2025.

Latest MRNA News

Moderna Underweight with $40 December 2026 Price Target — May 20, 2026
Moderna Shares Rally 13% as Hantavirus Outbreak Spurs Preclinical mRNA Efforts — May 16, 2026
Moderna Named No.1 Impactful Company, Gains EU Approval for mCOMBRIAX® and Expands Partnerships — May 12, 2026
Moderna Launches Preclinical Hantavirus Vaccine Research, Shares Surge — May 11, 2026
Moderna Outperform Rating After 26.6% Flu Vaccine Efficacy and Hantavirus Success — May 8, 2026

Recent MRNA Insider Trades

Hoge Stephen sold 53.34K (~$2.58M) on May 15, 2026.
Hussain Abbas sold 5.68K (~$264.95K) on May 1, 2026.
Klinger Shannon Thyme sold 13.88K (~$726.05K) on Mar 2, 2026.

MRNA Analyst Consensus

15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.73.

Common questions about MRNA

Who owns MRNA stock?: Hedge funds tracked by Rallies that own MRNA include Matrix Capital, Coatue Management, Bridgewater Associates, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Moderna.
Does Rallies show 13F holders for MRNA?: Yes. Rallies tracks hedge fund and 13F ownership data for MRNA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MRNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.